Back to resultsStudy to Demonstrate Cognitive Enhancing Effects of BF2.649
Primary Purpose
Schizophrenia
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
BF2.649
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Schizophrenia focused on measuring schizophrenia, cognitive deficients, cognitive enhancing, antipsychotics
Eligibility Criteria
Inclusion Criteria:
- DSM-IV diagnosis of schizophrenia and schizoaffective disorder and not experiencing an acute exacerbation of severe psychosis
- Stable antipsychotic drug treatment for at least 4 weeks of Abilify or Haldol or willing to switch to either of these two APDs.
- Able to execute written informed consent.
- Males and females, between the ages of 18-55 years old, in good health (based on medical history, physical examination, electrocardiograms, and clinical laboratory tests)
- All races and ethnicities fluent and literate in English.
Exclusion Criteria:
- Diagnosis of DSM-IV alcohol or substance abuse within the last month or DSM-IV alcohol or substance dependence within the last 3 months.
- Patients on a stable regimen of antipsychotic medication (other than Haldol or Abilify) for a minimum of 3 months who are not experiencing psychotic symptoms.
- Clinically significant abnormal pre-admission vital signs, EKGs, or clinical laboratory evaluations, in which the principle investigator deems the subject-volunteer ineligible for the study.
- Any patient scheduled to undergo any surgical procedure during the duration of the study
- Patients suffering an acute psychotic episode within the previous 30 days as determined by the attending physician or Principal Investigator.
- Patients on any antihistaminergic antipsychotic medications who are not willing to switch to either Haldol or Abilify.
- Any patient who has received any known hepatic or renal clearance altering agents (e.g., erythromycin, cimetidine, barbiturates, phenothiazines, etc.) for a period of 3 months before the first dose of study medication
- Patients taking any concurrent medications for a major medical illness.
- Any patients who test positive for HIV.
- Any patient testing positive for Hepatitis B or C whose liver panel (taken during clinical laboratories) reports clinically significant abnormalities of liver enzyme ranges suggesting a cirrhotic stage.
- Any patient who has donated plasma or blood within 30 days before the first dose of study medication
- Concurrent treatment with electroconvulsive therapy.
- Pregnant women, women in the child bearing age without an efficacious contraceptive device, or women who are breast feeding.
- Mental capacity is limited to the extent that the patient cannot provide legal consent or understand information regarding the side effects or tolerance of the study drug
- Any patient judged by the principal investigator to be inappropriate for the study.
Sites / Locations
- UT Southwestern Medical Center
- The University of Texas Southwestern Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Active Comparator
Arm Label
Placebo
BF2.649
Arm Description
Volunteers are given Placebo, up to 20mg per day
Volunteers are given BF2.649, up to 20mg per day
Outcomes
Primary Outcome Measures
Changes in Delayed Recall From Baseline to 12 Weeks
The Brief Visuospatial Memory Test-Revised (Delayed Recall) is a neuropsychological test to assess one's ability to recall a previously exposed stimuli. The t-score range (as being reported) is from 35-81, with higher scores being better and indicating being able to recall more items after a 45-minute delay. (The t-score is a score calculated from the individual score and based on each individual's age group.) The t-scores are then grouped together and reported as a mean with the standard deviation.
Secondary Outcome Measures
To Evaluate the Effect of BF2.649 on Symptom Severity Between Baseline and Week 12
Montgomery-Asberg Depression Rating Scale (MADRS), a depression rating scale. The score can total from 0-60, with the higher score indicating more severe depressive symptoms. The scores indicate a change between baseline and 12 weeks.
Full Information
NCT ID
NCT00690274
First Posted
June 2, 2008
Last Updated
March 29, 2019
Sponsor
University of Texas Southwestern Medical Center
Collaborators
Bioprojet, Stanley Medical Research Institute
1. Study Identification
Unique Protocol Identification Number
NCT00690274
Brief Title
Study to Demonstrate Cognitive Enhancing Effects of BF2.649
Official Title
A Randomized, Double Blind, Placebo Controlled, Study to Demonstrate the Cognitive Enhancing Effects of BF2.649 in People With Schizophrenia and Schizoaffective Disorder
Study Type
Interventional
2. Study Status
Record Verification Date
March 2019
Overall Recruitment Status
Completed
Study Start Date
June 2008 (undefined)
Primary Completion Date
October 2011 (Actual)
Study Completion Date
October 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Texas Southwestern Medical Center
Collaborators
Bioprojet, Stanley Medical Research Institute
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
To evaluate the cognitive enhancing effect of BF2.649 and to evaluate the effect of BF2.649 on symptom severity in persons with schizophrenia or schizoaffective disorder.
Detailed Description
We will recruit persons with schizophrenia or schizoaffective disorder who are not currently experiencing an acute exacerbation of psychotic symptoms, but still display cognitive symptoms and have consequent psychosocial dysfunction. The subjects recruited will be taking haloperidol, aripiprazole, risperidone or paliperidone. Each study subject will spend 4 weeks on a fixed dose of his or her APD with stable symptoms, during which time the baseline workup will be completed. At baseline (Week 0), each study subject will have a full symptom evaluation, side effects, and neuropsychological battery along with the full clinical laboratory and baseline safety study workup. Next, subjects, while remaining on their APD, will be randomized to BF2.649 or placebo. The dose of BF2.649 will be up to 20 mg/day. Assessment of safety parameters (vital signs, EKGs, clinical labs) and side effects (adverse events, BAS, SAS) will occur once weekly for the first 4 weeks (through study week 4) and then every other week for the next 4 weeks (to study week 8) including End of Study (week 12). An EEG will be taken at Week 1 and then at Week 8. Symptomatic outcome measures (PANSS and CGI) will be measured every two weeks during the double blind phase and at end of study. The neuropsychological battery will be done first at baseline and repeated at the end of the 8-week double blind phase. After 8 weeks of medication, the double-blinded drug will be stopped and the patient followed for a period 4 weeks with clinical and side effect measures recorded weekly with the exception of clinical laboratories, which will be recorded every other week. Each study participant will be seen weekly throughout the protocol for clinical assessment.
Finally, persons with schizophrenia display severe deficits in neuropsychological, cognitive, and social functioning. Our primary outcome measure will be to determine if BF2.649 can produce a cognitive enhancing effect and repair some of the neuropsychological deficiencies seen in this population. Therefore, blood samples will be collected from study volunteers for DNA analysis, serology testing, and white cell immortalization during and only at the baseline phase of the study (Week 0). If a therapeutic effect is seen, it will be important to be able to identify the genetic characteristics of the responders to BF2.649.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Schizophrenia
Keywords
schizophrenia, cognitive deficients, cognitive enhancing, antipsychotics
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
52 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Volunteers are given Placebo, up to 20mg per day
Arm Title
BF2.649
Arm Type
Active Comparator
Arm Description
Volunteers are given BF2.649, up to 20mg per day
Intervention Type
Drug
Intervention Name(s)
BF2.649
Other Intervention Name(s)
Study medication
Intervention Description
up to 20mg per day
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
cornstarch capsule
Intervention Description
up to 20mg per day
Primary Outcome Measure Information:
Title
Changes in Delayed Recall From Baseline to 12 Weeks
Description
The Brief Visuospatial Memory Test-Revised (Delayed Recall) is a neuropsychological test to assess one's ability to recall a previously exposed stimuli. The t-score range (as being reported) is from 35-81, with higher scores being better and indicating being able to recall more items after a 45-minute delay. (The t-score is a score calculated from the individual score and based on each individual's age group.) The t-scores are then grouped together and reported as a mean with the standard deviation.
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
To Evaluate the Effect of BF2.649 on Symptom Severity Between Baseline and Week 12
Description
Montgomery-Asberg Depression Rating Scale (MADRS), a depression rating scale. The score can total from 0-60, with the higher score indicating more severe depressive symptoms. The scores indicate a change between baseline and 12 weeks.
Time Frame
12 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
DSM-IV diagnosis of schizophrenia and schizoaffective disorder and not experiencing an acute exacerbation of severe psychosis
Stable antipsychotic drug treatment for at least 4 weeks of Abilify or Haldol or willing to switch to either of these two APDs.
Able to execute written informed consent.
Males and females, between the ages of 18-55 years old, in good health (based on medical history, physical examination, electrocardiograms, and clinical laboratory tests)
All races and ethnicities fluent and literate in English.
Exclusion Criteria:
Diagnosis of DSM-IV alcohol or substance abuse within the last month or DSM-IV alcohol or substance dependence within the last 3 months.
Patients on a stable regimen of antipsychotic medication (other than Haldol or Abilify) for a minimum of 3 months who are not experiencing psychotic symptoms.
Clinically significant abnormal pre-admission vital signs, EKGs, or clinical laboratory evaluations, in which the principle investigator deems the subject-volunteer ineligible for the study.
Any patient scheduled to undergo any surgical procedure during the duration of the study
Patients suffering an acute psychotic episode within the previous 30 days as determined by the attending physician or Principal Investigator.
Patients on any antihistaminergic antipsychotic medications who are not willing to switch to either Haldol or Abilify.
Any patient who has received any known hepatic or renal clearance altering agents (e.g., erythromycin, cimetidine, barbiturates, phenothiazines, etc.) for a period of 3 months before the first dose of study medication
Patients taking any concurrent medications for a major medical illness.
Any patients who test positive for HIV.
Any patient testing positive for Hepatitis B or C whose liver panel (taken during clinical laboratories) reports clinically significant abnormalities of liver enzyme ranges suggesting a cirrhotic stage.
Any patient who has donated plasma or blood within 30 days before the first dose of study medication
Concurrent treatment with electroconvulsive therapy.
Pregnant women, women in the child bearing age without an efficacious contraceptive device, or women who are breast feeding.
Mental capacity is limited to the extent that the patient cannot provide legal consent or understand information regarding the side effects or tolerance of the study drug
Any patient judged by the principal investigator to be inappropriate for the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Carol A Tamminga, MD
Organizational Affiliation
UT Southwestern Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
UT Southwestern Medical Center
City
Dallas
State/Province
Texas
ZIP/Postal Code
75390-9127
Country
United States
Facility Name
The University of Texas Southwestern Medical Center
City
Dallas
State/Province
Texas
ZIP/Postal Code
75390
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Study to Demonstrate Cognitive Enhancing Effects of BF2.649
We'll reach out to this number within 24 hrs